“Dr. Chen, is there really no other medicine?” Faced with the anxious tears of the family, Dr. Chen’s heart was full of helplessness. He clearly knows that a new targeted drug that can accurately correspond to the patient’s genetic mutation has just been approved abroad, but the drug license has not yet been obtained in Taiwan. In order to save his life, he decided to launch a project import for patients, but in the next few weeks, he was stuck in cumbersome regulatory documents and asking about overseas sources.
This is not a special case, but a “drug dilemma” that is being staged every day in Taiwan’s clinical field. According to industry statistics, Taiwan’s new drug launches lag behind Europe and the United States by an average of 12 to 24 months. For specific rare diseases or special cancers, the waiting period is even longer. Thousands of patients each year face a desperate situation where existing standard treatments are ineffective in a race against time.
When conventional pathways don’t work, physicians often choose to initiate the Name Patient Program (NPP). However, this well-intentioned and life-saving regulatory channel is often difficult to implement.
🚨 Clinical pain points: Why does “case project import” always hit a wall everywhere?
The core ethos of NPP is “patient-centric”, but this has become the biggest pain point in the supply chain:
- “Sporadic number” market failures: NPP cases are usually for a single or very small number of patients, and may only require a few boxes of medication at a time. For traditional large pharmaceutical distributors, such “very small” orders do not have an economic scale.
- High administrative and time costs: For these boxes of medicines, distributors must invest a lot of manpower to find overseas sources, handle cumbersome cross-border logistics, ensure cold chain effectiveness, and face strict project import regulations under the TFDA.
- “Thankless” real-world considerations: With the combination of low profits and high administrative costs, most dealers are often reluctant to assist in handling such NPP cases. This leads to doctors facing the dilemma of “finding no one to help import” even if they are willing to apply for patients.
For pharmaceutical companies, when important KOL doctors put forward such niche medication needs to you, they are often limited by the company’s internal operational organization and can only decline, missing the opportunity to establish a deep revolutionary relationship with the doctor.
💡 The solution to the adoption strategy: a flexible hub for “global drug finding” and “compliant import”
Seeing the dual dilemmas of the clinical side and the pharmaceutical company, PatientsForce officially launched the “Taiwan Project Imported Drug (EAP/NPP) Support Program”. We are committed to being the key driver of that “willingness to take on challenges”:
🌍 1. International distribution is in line with the supply of drugs in “flexible quantities”
We understand that behind every NPP case lies an anxious life. Caizhao has established strategic cooperation with many international pharmaceutical distributors and supply platforms in Europe, the United States and Asia. Through this global network, we have “flexible scheduling capabilities” to help match legitimate sources according to demand, breaking the limitations of traditional dealers “low quantity and not enough”.
📝 2. One-stop TFDA compliant import application
Project imports are not simple cross-border online shopping, but strict legal battles. We have a professional regulatory (RA) and project management team, from assisting physicians in confirming the plan (Form A / Form B), organizing original factory certification documents, to docking with TFDA for project approval applications, we provide “full-process compliance agency services”, allowing doctors to return their valuable time to clinical consultations.
🤝 3. Fill the “long-tail service gap” of big pharmaceutical companies
This is exactly the value we create for your company. When you are faced with a request from a KOL for a non-main product, orphan drug, or a very small number of NPPs, you don’t need to say “sorry” to the doctor, but you can say “We can ask the licensing team to help you.” Let us act as your external special forces to handle these administrative cumbersome and sporadic cases, and strengthen your critical doctor-patient relationship and channel trust.
Your pain points are solved by taking photos
“Global Drug Search” is not only a logistics service, but also a commitment to life and the highest support for the doctor’s profession.
We look forward to being the most flexible and reliable support for your company in the face of clinical “long-tail needs”. The photography team will be happy to arrange a short online exchange to show you in detail how we can solve these sporadic import problems that cause headaches in the industry through our global resource network. 👉 Join PF LINE@ solve the problem of finding medicine for you
